Multiple Myeloma Survival Rate With Stem Cell Transplant

The long term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines a large review study reports.

Multiple myeloma survival rate with stem cell transplant.

For example if the 5 year relative survival rate for a specific stage of multiple myeloma is 60 it means that people who have that cancer are on average about 60 as likely as people who don t have that cancer to live for. Before the transplant drug treatment is used to reduce the number of myeloma cells in the patient s body. All things considered while the autologous transplant can make the myeloma go away for a period of time even years it does not cure the growth and inevitably the myeloma back. A stem cell transplant replaces diseased stem cells with healthy ones and is often used to treat this form of cancer.

Stem cell transplant is commonly used to treat multiple myeloma. Treatment options for myeloma have expanded in. Multiple myeloma isn t considered curable but symptoms wax and wane. The widespread use of high dose therapy and autologous stem cell transplantation asct as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma mm enabling long term survival.

There can be a long period of dormancy that could. The transplant of this kind is the standard treatment for patients with various myeloma. Multiple myeloma survival rate after stem cell transplant. We here analyze factors influencing survival in 865 newly diagnosed mm patien.

A relative survival rate compares people with the same type and stage of cancer to people in the overall population. Findings from a phase 3 clinical trial note that patients with multiple myeloma who receive upfront autologous stem cell transplant asct typically live longer without disease. See drug therapy for multiple myeloma stem cell transplants sct can be autologous or allogeneic. Older patients and those with low risk disease show the greatest gains over time while people with high risk factors showed the least change its researchers said.

A person with multiple myeloma is likely to have a low blood count. In some cases a bone marrow or stem cell transplant is an option. Autologous stem cell transplantation autosct has an important role in the treatment of patients with symptomatic multiple myeloma mm.